Vaxil BioVXLLF -85.27%38 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates VXLLF with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Vaxil Bio ranks worse than 105932.1% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vaxil Bio's EBITDA for the
three
months ended in Mar. 2026 was $-0.08 Mil. Vaxil Bio's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Vaxil Bio's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
Vaxil Bio (OTCPK:VXLLF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vaxil Bio EBITDA Margin % Related Terms
Vaxil Bio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vaxil Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VXLLF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Vaxil Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaxil Bio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaxil Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vaxil Bio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaxil Bio (VXLLF) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vaxil Bio and its competitors. According to the industry distribution chart, Vaxil Bio ranks #999999 out of 944 companies in the Biotechnology industry.
Is Vaxil Bio's EBITDA Margin % too high?
Vaxil Bio's current EBITDA Margin % is 0.00%. Based on the distribution chart, Vaxil Bio ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vaxil Bio has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vaxil Bio ranks #999999 out of 944 companies for EBITDA Margin %. This places Vaxil Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vaxil Bio and its competitors. Vaxil Bio's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (VXLLF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Vaxil Bio's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vaxil Bio (VXLLF), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
38GF Score
Get the complete analysis for VXLLF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VXLLF has been successfully added to your 
